U.S. Markets close in 16 mins

Heat Biologics, Inc. (HTBX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.1800+0.0800 (+1.95%)
As of 03:41PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.1000
Bid4.1900 x 1000
Ask4.2100 x 900
Day's Range4.0250 - 4.2200
52 Week Range3.7600 - 17.0000
Avg. Volume243,766
Market Cap106.161M
Beta (5Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)-1.3650
Earnings DateAug 05, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.67
  • GlobeNewswire

    Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

    Designed for rapid “plug and play” programming and stockpiling against emerging infectious agents and viral mutations Emergence of Omicron and other COVID-19 variants underscores the need for a rapid, safe, and effective response to potential biological threats RapidVax Presentation at the 2021 World Vaccine & Immunotherapy Congress West Coast and World Antiviral Congress 2021 DURHAM, N.C., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharma

  • Zacks Small Cap Research

    HTBX: Third Quarter Results

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Heat Biologics, Inc. (NASDAQ:HTBX) reported third quarter 2021 results on November 10, 2021 and filed its Form 10-Q with the SEC. Highlights for the third quarter ending September 30, 2021 and to date include: ➢ Groundbreaking for San Antonio facility - August 2021 ➢ Formation of and new additions to Biothreat Advisory Board

  • GlobeNewswire

    Heat Biologics Provides Third Quarter 2021 Business Update

    DURHAM, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), today provided strategic, financial, and operational updates for the third quarter ended September 30, 2021. Jeff Wolf, Chief Executive Officer of Heat, commented, “Our clinical and preclinical programs are progressing well. In September, we expanded dosing in our Phase 1 clinical trial of monoclonal antibody PTX-35 in patients with solid tumors, and are planning a clinical development pathway to utiliz